Skip to main content

Atorvastatin (Monograph)

Brand name: Lipitor
Drug class: HMG-CoA Reductase Inhibitors
- Statins
VA class: CV350
Molecular formula: ( C33H34FN2O5)2 • Ca • H2O
CAS number: 134523-03-8

Medically reviewed by Drugs.com on Dec 4, 2023. Written by ASHP.

Introduction

Antilipemic agent; hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (i.e., statin).1 18

Uses for Atorvastatin

Reduction in Risk of Cardiovascular Events

Adjunct to diet and lifestyle modifications400 in patients without clinical evidence of CHD who have multiple risk factors (e.g., age, smoking, hypertension, low HDL-cholesterol concentrations, family history of early CHD) to reduce the risk of MI, stroke, or angina and the risk of undergoing revascularization procedures.1

Adjunct to diet and lifestyle modifications400 in patients without clinical evidence of CHD who have type 2 diabetes mellitus and multiple risk factors (e.g., retinopathy, albuminuria, smoking, hypertension) to reduce the risk of MI or stroke.1

Adjunct to diet and lifestyle modifications400 in patients with clinical evidence of CHD to reduce the risk of nonfatal MI, fatal and nonfatal stroke, angina, or hospitalization for CHF, and the risk of undergoing revascularization procedures.1 53 54 66 68 71

May use in fixed combination with amlodipine when treatment with both atorvastatin (for prevention of cardiovascular events) and amlodipine (for hypertension and/or CAD) is appropriate.65

Extensive evidence demonstrates that statins can substantially reduce LDL-cholesterol concentrations and associated risk of atherosclerotic cardiovascular disease (ASCVD); may be used for secondary prevention or primary prevention in high-risk patients.336 337 338 350 400

AHA/ACC cholesterol management guideline states that lifestyle modification is the foundation of ASCVD risk reduction.400 Patients with established ASCVD or high risk of ASCVD should also be treated with a statin.400

Because relative ASCVD risk reduction is correlated with degree of LDL-cholesterol lowering, use maximum tolerated intensity of a statin to achieve greatest benefit.400 High-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by ≥50%) is recommended; if high-intensity statin therapy not possible (e.g., because of a contraindication or intolerable adverse effect), may consider moderate-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by 30–49%).400 AHA/ACC considers atorvastatin 40–80 mg daily to be a high-intensity statin and atorvastatin 10–20 mg daily to be a moderate-intensity statin.400

The addition of a nonstatin drug (e.g., ezetimibe, PCSK9 inhibitor) to statin therapy may be considered in certain high-risk patients who require further reduction in LDL-cholesterol concentrations, particularly if there is evidence from randomized controlled studies suggesting that the addition of the nonstatin drug further reduces ASCVD events.400

When considering whether to initiate statin therapy for primary prevention, AHA/ACC recommends an individualized approach and shared decision making between patient and clinician.400 According to the guidelines, statin therapy may be considered in certain high-risk groups such as adults 20–75 years of age with LDL cholesterol ≥190 mg/dL, adults 40–75 years of age with diabetes mellitus, adults 40–75 years of age without diabetes mellitus but with LDL-cholesterol levels ≥70 mg/dL and an estimated 10-year ASCVD risk ≥7.5%, and adults 40–75 years of age with chronic kidney disease (not treated with dialysis or transplantation) and LDL-cholesterol concentrations of 70–189 mg/dL who have a 10-year ASCVD risk ≥7.5%.400

Dyslipidemias

Adjunct to nondrug therapies (e.g., dietary management) in adults to decrease elevated serum total cholesterol, LDL-cholesterol, apolipoprotein B (apo B), and triglyceride concentrations, and to increase HDL-cholesterol concentrations in the management of primary hypercholesterolemia (heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIa or IIb).1 May use in combination with ezetimibe for additive antilipemic effects.64 Also used in combination with fenofibrate to decrease triglyceride concentrations and increase HDL-cholesterol concentrations in patients with mixed dyslipidemia and CHD (or CHD risk equivalents) who are on optimal statin therapy; however, no incremental benefit on cardiovascular morbidity and mortality beyond that provided by statin monotherapy.78 79

Adjunct to nondrug therapies (e.g., dietary management) to decrease elevated serum total cholesterol, LDL-cholesterol, and apo B concentrations in the management of heterozygous familial hypercholesterolemia in boys and postmenarchal girls 10–17 years of age who, despite an adequate trial of dietary management, have a serum LDL-cholesterol concentration of ≥190 mg/dL or a serum LDL-cholesterol concentration of ≥160 mg/dL and either a family history of premature cardiovascular disease or ≥2 other cardiovascular risk factors.1

Adjunct to nondrug therapies (e.g., dietary management) for the management of primary dysbetalipoproteinemia (Fredrickson type III).1

Adjunct to nondrug therapies (e.g., dietary management) for the management of elevated serum triglyceride concentrations (Fredrickson type IV).1

Reduction of elevated serum total and LDL-cholesterol concentrations in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies (e.g., plasma LDL-apheresis) or when such therapies are not available.1 May use in combination with ezetimibe for additive antilipemic effects.64

Has reduced total and LDL-cholesterol concentrations in patients with hypercholesterolemia associated with or exacerbated by renal transplantation [off-label]8 38 39 undergoing use of protease inhibitors [off-label].21 37

Has reduced total and LDL-cholesterol concentrations in hypercholesterolemic patients undergoing peritoneal dialysis [off-label].34

May use in fixed combination with amlodipine when treatment with both atorvastatin (for dyslipidemias) and amlodipine (for hypertension and/or CAD) is appropriate.65

Atorvastatin Dosage and Administration

General

Patient Monitoring

Administration

Oral Administration

Administer orally at any time of day without regard to meals.1 7

Dosage

Available as atorvastatin calcium; dosage expressed in terms of atorvastatin.1 65

Dosage modifications may be necessary when used concomitantly with certain drugs (see Specific Drugs and Foods under Interactions).1

Pediatric Patients

Dyslipidemias
Heterozygous Familial Hypercholesterolemia
Oral

Children 10–17 years of age: Initially, 10 mg once daily.1

Adjust dosage at intervals of ≥4 weeks until the desired effect on lipoprotein concentrations is observed or a daily dosage of 20 mg is reached.1

Adults

Reduction in Risk of Cardiovascular Events
Oral

Use maximally tolerated statin intensity to achieve optimal ASCVD risk reduction.400 High-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by ≥50%) is preferred; if high-intensity statin therapy not possible (e.g., because of a contraindication or intolerable adverse effect), may consider moderate-intensity statin therapy (defined as reducing LDL-cholesterol concentrations by 30–49%).400

The AHA/ACC guideline panel considers atorvastatin 40–80 mg daily to be a high-intensity statin and atorvastatin 10–20 mg daily to be a moderate-intensity statin.400

Dyslipidemias
Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) or Mixed Dyslipidemia
Oral

Initially, 10 or 20 mg once daily.1

Patients who require reductions of >45% in LDL-cholesterol concentration: May initiate therapy with 40 mg once daily.1

Usual maintenance dosage: 10–80 mg once daily.1

Homozygous Familial Hypercholesterolemia
Oral

10–80 mg once daily.1

Atorvastatin/Amlodipine Fixed-combination Tablets (Caduet)
Oral

Patients currently receiving atorvastatin in combination with amlodipine: Use fixed combination as a substitute for the individually titrated drugs.65 Can switch to the fixed-combination preparation containing corresponding individual doses of atorvastatin and amlodipine; alternatively, can increase the dosage of one or both components for additional antihypertensive, antianginal, and/or antilipemic effects.65

Patients currently receiving either atorvastatin or amlodipine: Use fixed combination to provide additional therapy.65 Select atorvastatin and amlodipine doses independently.65

Patients currently receiving neither atorvastatin nor amlodipine: Use fixed combination to initiate treatment in patients requiring therapy for dyslipidemias and hypertension and/or angina.65 Select atorvastatin and amlodipine doses independently.65

Prescribing Limits

Pediatric Patients

Dyslipidemias
Oral

Children 10–17 years of age: Maximum 20 mg daily.1

Special Populations

Hepatic Impairment

No specific dosage recommendations.1 (See Hepatic Impairment under Cautions and see Special Populations under Pharmacokinetics.)

Renal Impairment

Dosage modification not required.1

Geriatric Patients

No specific dosage recommendations; however, use with caution.1 (See Geriatric Use under Cautions.)

Cautions for Atorvastatin

Contraindications

Warnings/Precautions

Musculoskeletal Effects

Myopathy (defined as muscle pain or weakness in conjunction with CK [CPK] concentration increases >10 times the ULN) reported occasionally.1

Rhabdomyolysis with acute renal failure secondary to myoglobinuria reported rarely.1

Immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, reported rarely in patients receiving statins.1 Characterized by proximal muscle weakness and elevated CK concentrations that persist despite discontinuance of statin therapy, necrotizing myopathy without substantial inflammation, and improvement following therapy with immunosuppressive agents.1

Risk of myopathy or rhabdomyolysis increased in geriatric patients (≥65 years of age) and in patients with uncontrolled hypothyroidism or renal impairment.1

Certain drug or food interactions also may increase risk of myopathy and/or rhabdomyolysis.1 (See Interactions.)

May consider periodic monitoring of CK concentrations; however, there is no assurance that such monitoring will prevent severe myopathy.1

AHA/ACC recommends measurement of CK levels in patients with severe statin-associated muscle symptoms; however, routine monitoring is not useful.400

Consider myopathy in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked increases in CK concentrations.1

Discontinue therapy if serum CK concentrations become markedly elevated or if myopathy is diagnosed or suspected.1

Temporarily withhold or discontinue therapy in any patient experiencing an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection; hypotension; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; uncontrolled seizures).1

Hepatic Effects

Increases in serum aminotransferase (AST, ALT) concentrations reported.1 Concentrations returned to or near pretreatment levels following dosage reduction or therapy interruption or discontinuance.1 Not associated with jaundice or other clinical manifestations.1

Fatal and nonfatal hepatic failure reported rarely.1

Perform liver function tests before initiation of therapy and as clinically indicated (e.g., presence of manifestations suggestive of liver damage201 ).1 Serious statin-related liver injury is rare and unpredictable, and routine periodic monitoring of liver enzymes does not appear to be effective in detecting or preventing serious liver injury.200 AHA/ACC cholesterol management guideline states that it is reasonable to obtain liver function tests in patients with symptoms of hepatotoxicity (e.g., unusual fatigue or weakness, loss of appetite, abdominal pain, dark colored urine, yellowing of skin or sclera); however, routine monitoring not recommended.350 400

If serious liver injury with clinical manifestations and/or hyperbilirubinemia or jaundice occurs, promptly interrupt atorvastatin therapy.1 If an alternate etiology is not found, do not restart atorvastatin.1

Hyperglycemic Effects

Increases in HbA1c and fasting serum glucose concentrations reported.1 200 Possible increased risk of developing diabetes.200 May need to monitor glucose concentrations following initiation of statin therapy.201

AHA/ACC cholesterol management guideline states that in patients with increased risk of diabetes mellitus or new-onset diabetes mellitus, statin therapy and lifestyle modifications should be continued to reduce risk of ASCVD.400

Endogenous Steroid Production

Statins interfere with cholesterol synthesis and theoretically may blunt adrenal and/or gonadal steroid production.1

No effects on basal plasma cortisol concentration or adrenal reserve observed with atorvastatin.1 Effects on male fertility or on pituitary-gonadal axis in premenopausal women not fully established.1

Caution advised if a statin or another antilipemic agent is used concomitantly with drugs that may decrease concentrations or activity of endogenous steroid hormones (e.g. ketoconazole, spironolactone, cimetidine).1

Cognitive Impairment

Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) reported rarely.1

Generally nonserious and reversible, with variable times to symptom onset (1 day to years) and resolution (median of 3 weeks following discontinuance of therapy).1 200 Not associated with fixed or progressive dementia (e.g., Alzheimer’s disease) or clinically important cognitive decline.200 Not associated with any specific statin, patient's age, statin dosage, or concomitant drug therapy.200

FDA states that cardiovascular benefits of statins outweigh the small increased risk of cognitive impairment.200

If manifestations consistent with cognitive impairment occur, National Lipid Association (NLA) statin safety assessment task force recommends evaluating and managing patients appropriately.202

Use in Patients with Recent Stroke or TIA

In hypercholesterolemic patients without clinically evident CHD who had a stroke or TIA within the past 1–6 months, long-term (median of 4.9 years) therapy with high-dose atorvastatin (80 mg daily) associated with higher incidence of hemorrhagic stroke compared with placebo.1 73 Risk is increased in patients with history of hemorrhagic or lacunar stroke.1 75

Increases in aminotransferase or CK concentrations (≥3 or >10 times the ULN, respectively) reported more frequently in such patients receiving high-dose atorvastatin compared with placebo.1 Diabetes also reported more frequently in such patients receiving high-dose atorvastatin.1

Role as Adjunct Therapy

Prior to institution of antilipemic therapy, vigorously attempt to control serum cholesterol by appropriate dietary regimens, weight reduction, exercise, and treatment of any underlying disorder that might be the cause of lipid abnormality.1

Use of Fixed Combinations

When used in fixed combination with amlodipine, consider cautions, precautions, contraindications, and interactions associated with amlodipine.65

Specific Populations

Pregnancy

All statins were previously contraindicated in pregnant women because fetal risk was thought to outweigh any possible benefit.405 However, the totality of evidence to date indicates limited potential for statins to cause malformations and other adverse embryofetal effects; FDA has therefore requested removal of the contraindication.405 Most pregnant patients should still discontinue statins because of the possibility of fetal harm; however, some patients (e.g., those with homozygous familial hypercholesterolemia or established cardiovascular disease) may benefit from continued therapy.400 405 Consider patient's individual risks and benefits.405

Patients who become pregnant or suspect that they are pregnant while receiving a statin should notify their clinician; clinician should advise patient on the appropriate course of action.405

Increased risk of miscarriage reported in pregnant women exposed to statins; however, not clear whether drug-related or due to other confounding factors.400 405

Lactation

Distributed into milk in rats; may distribute into milk in humans.1 Use is contraindicated in nursing women; women who require atorvastatin therapy should not breast-feed their infants.1 Many patients can stop statin therapy temporarily until breast-feeding is complete; patients who require ongoing statin treatment should not breast-feed and should use alternatives such as infant formula.400 405

Pediatric Use

Safety and efficacy not established in prepubertal children or in children <10 years of age.1 Advise adolescent girls to use effective and appropriate contraceptive methods during therapy to reduce the likelihood of unintended pregnancy.1

Safety and efficacy of atorvastatin in fixed combination with amlodipine not established in children.65

Geriatric Use

No overall differences in efficacy or safety relative to younger adults, but increased sensitivity cannot be ruled out.1 (See Special Populations under Pharmacokinetics.)

Use with caution, since age ≥65 years is a predisposing factor for myopathy.1

Patients >75 years of age may have a higher risk of adverse effects and lower adherence to therapy; consider expected benefits versus adverse effects before initiating statin therapy in this population.400

Safety and efficacy of atorvastatin in fixed combination with amlodipine not established in geriatric patients.65

Hepatic Impairment

Use with caution in patients who consume substantial amounts of alcohol and/or have a history of liver disease.1

Contraindicated in patients with active liver disease or unexplained, persistent increases in serum aminotransferase concentrations.1

Renal Impairment

Dosage modification not necessary in patients with renal impairment.1 However, monitor more closely for adverse musculoskeletal effects, since history of renal impairment may be a risk factor for development of rhabdomyolysis.1

Safety and efficacy not established in patients with end-stage renal disease (ESRD); hemodialysis not expected to substantially enhance clearance since atorvastatin is extensively bound to plasma proteins.1

Common Adverse Effects

Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain.1

Drug Interactions

Metabolized by CYP3A4; does not inhibit CYP3A4.1

When used in fixed combination with amlodipine, consider interactions associated with amlodipine.65 No formal drug interaction studies to date with fixed-combination preparation.65

Drugs and Foods Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP3A4: Potential pharmacokinetic interaction (variable increases in plasma atorvastatin concentrations); increased risk of myopathy or rhabdomyolysis.1 Carefully monitor for unexplained muscle pain, tenderness, or weakness, particularly following initiation of atorvastatin therapy or an increase in dosage of either drug.1 (See Specific Drugs and Foods under Interactions.)

Inducers of CYP3A4: Potential pharmacokinetic interaction (variable reductions in plasma atorvastatin concentrations).1 (See Specific Drugs and Foods under Interactions.)

Drugs Transported by Organic Anion Transport Polypeptide 1B1

Inhibitors of organic anion transport polypeptide (OATP) 1B1: Potential pharmacokinetic interaction (increased bioavailability of atorvastatin).1

Specific Drugs and Foods

Drug

Interaction

Comments

Amlodipine

Modest increase in atorvastatin exposure1

Not clinically relevant1

Antacids

Decreased plasma atorvastatin concentrations1

Antifungals, azoles

Increased risk of myopathy or rhabdomyolysis1

Itraconazole: Increased atorvastatin peak plasma concentration and AUC1

Weigh benefits against risks of concomitant use; carefully monitor for muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Itraconazole: Use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 20 mg daily1

Bile acid sequestrants

Additive cholesterol-lowering effects20

Decreased absorption of atorvastatin63

Administer statins 1 hour before or 4 hours after the bile acid sequestrant63

Colchicine

Myopathy, including rhabdomyolysis, reported1

Use concomitantly with caution1

Cyclosporine

Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1 339

Avoid concomitant use1

Digoxin

Increased plasma digoxin concentrations1 339

Monitor appropriately1 339

Efavirenz

Possible variable reductions in plasma atorvastatin concentrations1

Fibric acid derivatives (e.g., fenofibrate, gemfibrozil)

Increased risk of myopathy1

Fenofibrate: Slight increase in atorvastatin AUC72

Gemfibrozil: Increased atorvastatin AUC1

Gemfibrozil: Avoid concomitant use1

Other fibric acid derivatives (e.g., fenofibrate): Use concomitantly with caution and only if benefits outweigh risks; consider lower initial and maintenance dosages of atorvastatin (i.e., low- or moderate-intensity statin therapy); carefully monitor for muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1 350

Grapefruit juice

Increased atorvastatin peak plasma concentration and AUC; more substantial increases in atorvastatin peak plasma concentration and/or AUC following ingestion of large quantities (≥750–1200 mL daily) of grapefruit juice1

Ingestion of large quantities (>1 L daily) of grapefruit juice may increase risk of myopathy1

HCV antivirals

Glecaprevir and pibrentasvir: Plasma concentrations of atorvastatin increased by 8.3-fold1

Elbasvir and grazoprevir: Plasma concentrations of atorvastatin increased by 1.9-fold1

Glecaprevir and pibrentasvir: Concomitant use not recommended1

Elbasvir and grazoprevir: Do not exceed atorvastatin dosage of 20 mg daily1

HIV protease inhibitors

Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1

Weigh benefits against risks of concomitant use; carefully monitor for unexplained muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Ritonavir-boosted darunavir, fosamprenavir or ritonavir-boosted fosamprenavir, or ritonavir-boosted saquinavir: Use concomitantly with caution; use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 20 mg daily1

Lopinavir/ritonavir: Use concomitantly with caution; use lowest necessary dosage of atorvastatin1

Nelfinavir: Monitor closely;1 use lowest necessary dosage of atorvastatin and do not exceed atorvastatin dosage of 40 mg daily1

Ritonavir-boosted tipranavir: Avoid concomitant use1

Letermovir

Increased exposure of atorvastatin; magnitude of interaction may be greater when letermovir is coadministered with cyclosporine1

Do not exceed atorvastatin dosage of 20 mg daily1

Use of atorvastatin not recommended in patients receiving both letermovir and cyclosporine1

Lomitapide

Increased peak plasma concentration and AUC of atorvastatin acid374

Adjustment of atorvastatin dosage not required; however, do not exceed lomitapide dosage of 30 mg daily374

Macrolides (i.e., clarithromycin, erythromycin)

Clarithromycin, erythromycin: Increased atorvastatin peak plasma concentration and AUC; increased risk of myopathy or rhabdomyolysis1

Weigh benefits against risks of concomitant use; carefully monitor for unexplained muscle pain, tenderness, or weakness, particularly during initial months of therapy and following an increase in dosage of either drug1

Clarithromycin: Use concomitantly with caution; use lowest necessary dosage of atorvastatin; do not exceed atorvastatin dosage of 20 mg daily1

Erythromycin: Use concomitantly with caution; consider using lower initial and maintenance dosages of atorvastatin1

Niacin (antilipemic dosages [≥1 g daily])

Increased risk of myopathy1

Increased risk of severe adverse effects (disturbances in glycemic control requiring hospitalization, development of diabetes mellitus, adverse GI effects, myopathy, gout, rash, skin ulceration, infection, bleeding) with concomitant use of niacin (1.5–2 g daily) and simvastatin (40–80 mg daily, with or without ezetimibe)369 371

Weigh benefits against risks of concomitant use1

Use concomitantly with caution; consider using lower initial and maintenance dosages of atorvastatin; carefully monitor patients for unexplained muscle pain, tenderness, or weakness, particularly during initial months of atorvastatin therapy or following an increase in dosage of either drug1

Omega-3-acid ethyl esters

No effect on rate or extent of exposure to atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady state373

Oral contraceptives

Increased peak plasma concentrations and AUC of ethinyl estradiol and norethindrone1

Caution when selecting an oral contraceptive1

Rifampin

Variable effects on plasma atorvastatin concentrations;2 because delayed administration of atorvastatin following administration of rifampin associated with substantial reductions in plasma atorvastatin concentrations1

Administer simultaneously

Warfarin

No clinically important effect on PT1

Some experts recommend closer monitoring of INR when statin therapy is initiated or adjusted339

Atorvastatin Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed following oral administration; undergoes extensive first-pass metabolism in the liver.1

Peak plasma concentrations attained at 1–2 hours.1

Absolute bioavailability is approximately 14%.1

Evening administration associated with a decrease in the extent of absorption;1 however, antilipemic activity remains unchanged.1

Onset

Therapeutic response usually is apparent within 2 weeks; maximal response occurs within 4 weeks.1

Food

Food decreases rate and extent of absorption but does not alter antilipemic effects.1

Special Populations

Hepatic impairment (Child-Pugh class A and B) or alcoholic liver disease: Substantially increased concentrations.1

Geriatric patients: Peak plasma concentration and AUC are 40 and 30% higher, respectively, in geriatric individuals (≥65 years of age) compared with younger adults.1

Distribution

Extent

Statins are distributed mainly to the liver.129 130

Distributes into milk in rats; may distribute into human milk.1

Plasma Protein Binding

≥98% (principally albumin).1 129 130 131 132 133 134 135 136

Elimination

Metabolism

Extensively metabolized in the liver,1 mainly by CYP3A4,1 131 136 137 138 139 to active metabolites.1 129 130 131 140

Elimination Route

Excreted principally in feces; <2% of a dose excreted in urine.1

Half-life

Approximately 14 hours.1

Stability

Storage

Oral

Tablets

Atorvastatin: 20–25°C.1

Atorvastatin/amlodipine fixed combination: 25°C (may be exposed to 15–30°C).65

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Atorvastatin Calcium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

10 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

20 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

40 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

80 mg (of atorvastatin)*

Atorvastatin Calcium Tablets

Lipitor

Pfizer

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Atorvastatin Calcium Combinations

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

10 mg (of atorvastatin) with Amlodipine Besylate 2.5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

10 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

10 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

20 mg (of atorvastatin) with Amlodipine Besylate 2.5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

20 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

20 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

40 mg (of atorvastatin) with Amlodipine Besylate 2.5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

40 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

40 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

80 mg (of atorvastatin) with Amlodipine Besylate 5 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

80 mg (of atorvastatin) with Amlodipine Besylate 10 mg (of amlodipine)*

Atorvastatin Calcium and Amlodipine Besylate Tablets

Caduet

Pfizer

AHFS DI Essentials™. © Copyright 2024, Selected Revisions December 13, 2021. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Pfizer. Lipitor (atorvastatin calcium) tablets prescribing information. New York, NY; 2019 Nov.

2. Parke-Davis. Lipitor formulary information. Morris Plains, NJ; 1997 Feb.

5. Kastelein JJP, Isaacsohn JL, Ose L et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol. 2000; 86:221-3. http://www.ncbi.nlm.nih.gov/pubmed/10913488?dopt=AbstractPlus

7. Lea AP, McTavish D. Atorvastatin: A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 1997;53(5):828-847.

8. Nawrocki J, Schwartz S, Fayad R, et al. Atorvastatin, a new HMG-CoA reductase inhibitor is safe and effective in NIDDM with hyperlipidemia. Paper presented at 66th Congress of the European Atherosclerosis Society. Florence, Italy; 1996.

9. McKenney JM, McCormick LS, Weiss S et al. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med. 1998;104:137-43.

10. Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol. 1997;17:1793-9.

11. Parke-Davis, Morris Plains, NJ: Personal communication.

12. Heinonen T, Stein E, Issacsohn J, et al. Atorvastatin in the treatment of severe hypercholesterolemia. In: 66th Congress of the European Atherosclerosis Society Abstract Book: 1996 July 13-17, Florence Italy, 214. Abstract.

13. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG Co-A reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128-33.

15. Heinonen T, Black D. Atorvastatin monotherapy and combination therapy in the treatment of severe hypercholesterolemia. Atherosclerosis. 1995;115 (Suppl):S20. Abstract.

16. Bairaktari ET, Tzallas CS, Tsimihodimos VK, et al. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk. 1999;6:113-6.

17. Hunninghake D, Bakker-Arkema RG, Wigand JP, et al. Treating to meet NCEP-recommended LDL-cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease. J Fam Pract. 1998;47(5):349-56.

18. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL-C cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995;15:678-82.

19. Heinonen TM, Stein F, Weiss SR, et al. The lipid lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996;18(5):853-63.

20. Heinonen TM, Schrott H, McKenney JM, et al. Atorvastatin, a new HMG-CoA reductase inhibitor as monotherapy and combined with colestipol. J Cardiovasc Pharmacol Therapeut. 1996;1(2):117-22.

21. Murillas J, Martin T, Ramos A et al. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS. 1999; 13:1424-5. http://www.ncbi.nlm.nih.gov/pubmed/10449305?dopt=AbstractPlus

22. Witzum JL. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman JG, Limbird LE, Molinoff PB et al eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill; 1996:875-97.

23. McVey D, Patel H, Eminton Z et al. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study. Int J Clin Pract. 1999; 53:509-13. http://www.ncbi.nlm.nih.gov/pubmed/10692735?dopt=AbstractPlus

24. Wierzbicki AS, Lumb PJ, Crook MA et al. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract. 1999; 53:609-11. http://www.ncbi.nlm.nih.gov/pubmed/10692755?dopt=AbstractPlus

25. Cilla DD, Gibson DM, Whitfield LR, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996;36:604-9.

26. Crouse JR, Frohlich J, Ose L, et al. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol. 1999;83:1476-80.

27. Dart A, Jerums G, Nicholson G, et al. A multicenter, double-blind, one year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol. 1997;80:39-44.

28. Raal FJ, Pilcher GJ, Veller MG et al. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999; 84:1344-6. http://www.ncbi.nlm.nih.gov/pubmed/10614803?dopt=AbstractPlus

30. Davidson MM, McKenney JM, Stein EA, et al. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1475-1481.

31. Stern R, Yang B, Horton M, et al. Renal dysfunction does not alter the pharmacokinetics or low density lipoprotein concentration reduction of atorvastatin. J Clin Pharmacol. 1997;37(9):816-9.

32. Gibson DM, Yang BB, Abel RB, et al. Effects of hepatic and renal impairment on pharmacokinetics (pk) and pharmacodynamics (pd) of atorvastatin (abstract). Pharm Res. 1996;13(suppl):428S.

33. Ginsberg HN, Goldberg IJ. Disorders of lipoprotein metabolism. In: Harrison’s principles of internal medicine. 14th ed. New York: McGraw-Hill Book Co; 1998:2138-49.

34. Hugnagel G, Michel C, Vrtovsnik F et al. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant. 2000; 15:684-8. http://www.ncbi.nlm.nih.gov/pubmed/10809811?dopt=AbstractPlus

35. Waters DD. Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial. Can J Cardiol. 2000; 16(suppl A):11-3A.

36. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Therapeut. 2000; 5:27-31.

37. Henry K, Melroe H, Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet. 1998;352:1031-2.

38. Velussi M, Cernigoi AM, Tortul C et al. Atorvastatin for the management of type 2 diabetic patients with dyslipidaemia: a mid-term (9 months) treatment experience. Diab Nutr Metab. 1999; 12:407-12.

39. Paolisso G, Barbagallo M, Petrella G et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000; 150:121-7. http://www.ncbi.nlm.nih.gov/pubmed/10781642?dopt=AbstractPlus

40. Raal FJ, Pappu AS, Illingworth DR et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000; 150:421-8. http://www.ncbi.nlm.nih.gov/pubmed/10856535?dopt=AbstractPlus

41. American Heart Association. AHA conference report on cholesterol. Circulation. 1989; 80:715-48. http://www.ncbi.nlm.nih.gov/pubmed/2670320?dopt=AbstractPlus

42. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23.

44. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol. 1997;79:1248-51.

45. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res. 1997;38:2071-78.

46. McKenney JM. Dyslipidemias. In: Applied therapeutics. the clinical use of drugs. 6th ed. Vancouver: Applied Therapeutics, Inc. 1995; 9-1-9-23.

47. Muck W, Frey R, Unger S et al. Pharmacokinetics of cerivastatin when administered under fasted and fed conditions in the morning or evening. Int J Clin Pharmacol Ther. 2000; 38:298-303. http://www.ncbi.nlm.nih.gov/pubmed/10890578?dopt=AbstractPlus

48. American Medical Association Council on Scientific Affairs. Dietary and pharmacologic therapy for the lipid risk factors. JAMA. 1983; 250:1873-9. http://www.ncbi.nlm.nih.gov/pubmed/6620484?dopt=AbstractPlus

49. Hoeg JM, Gregg RE, Brewer HB. An approach to the management of hyperlipoproteinemia. JAMA. 1986; 255:512-21. http://www.ncbi.nlm.nih.gov/pubmed/3510334?dopt=AbstractPlus

50. National Institutes of Health Office of Medical Applications of Research. Consensus conference: lowering blood cholesterol to prevent heart disease. JAMA. 1985;25:2080-6.

51. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES Study). Am J Cardiol. 1998;81:582-587.

52. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin, and simvastatin. J Am Coll Cardiol. 1998;32(3):665-72.

53. McCormick L, Black DM, Waters D, et al. Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with atorvastatin versus revascularization treatments (AVERT). Am J Cardiol. 1997;80:1130-33.

54. Pitt B, Waters D, Brown WV, et al. Aggresive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341(2):70-76.

56. Bertolini S, Bon GB, Campbell LM, et al. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis. 1997;130:191-7.

57. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest. 1983;72:743-7.

58. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Ann Rev Biochem. 1977; 46:897-930. http://www.ncbi.nlm.nih.gov/pubmed/197883?dopt=AbstractPlus

59. Parke-Davis, Morris Plains, NJ: Personal communication on the HMG-CoA Reductase Inhibitors General Statement.

60. Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97. http://www.ncbi.nlm.nih.gov/pubmed/11368702?dopt=AbstractPlus

61. Schwartz GG, Olsson AG, Ezekowitz MD et al for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study investigators. JAMA. 2001; 285:1711-8.

62. Anon. Choice of lipid-regulating drugs. Med Lett Drugs Ther. 2001; 43:43-8. http://www.ncbi.nlm.nih.gov/pubmed/11378632?dopt=AbstractPlus

63. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Adult Treatment Panel III Report. From AHA web site. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm

64. Merck & Co., Inc. Zetia (ezetimibe) tablets prescribing information. Whitehouse Station, NJ; 2013 Aug.

65. Pfizer Labs. Caduet (amlodipine besylate/atorvastatin calcium) tablets prescribing information. New York, NY; 2015 Mar.

66. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-504. http://www.ncbi.nlm.nih.gov/pubmed/15007110?dopt=AbstractPlus

67. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291: 1071-80. http://www.ncbi.nlm.nih.gov/pubmed/14996776?dopt=AbstractPlus

68. LaRosa JC, Grundy SM, Waters DD et al for the Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352:1425-35. http://www.ncbi.nlm.nih.gov/pubmed/15755765?dopt=AbstractPlus

69. Waters DD, Guyton JR, Herrington DM et al for the TNT steering committee members and investigators. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004; 93: 154-8.

70. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease—is it time to shift our goals? N Engl J Med. 2005; 352:1483-4.

71. Deedwania P, Barter P, Carmena R et al for the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006; 368:919–28. http://www.ncbi.nlm.nih.gov/pubmed/16962881?dopt=AbstractPlus

72. Abbott Laboratories. TriCor (fenofibrate) tablets prescribing information. North Chicago, IL; 2008 Jun.

73. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355:549-59. http://www.ncbi.nlm.nih.gov/pubmed/16899775?dopt=AbstractPlus

74. Kent DM. Stroke—An equal opportunity for the initiation of statin therapy. N Engl J Med. 2006; 355:613-5. http://www.ncbi.nlm.nih.gov/pubmed/16899782?dopt=AbstractPlus

75. Pfizer, New York, NY: Personal communication.

76. Parke-Davis. Lipitor (atorvastatin calcium) tablets prescribing information. New York, NY; 2007 Nov.

77. Merck & Co., Inc. Victrelis (boceprevir) capsules prescribing information. Whitehouse Station, NJ; 2012 Jul.

78. Abbvie. Trilipix (fenofibric acid) capsules prescribing information. North Chicago, IL; 2013 Mar.

79. ACCORD Study Group, Ginsberg HN, Elam MB et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563-74. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2879499&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/20228404?dopt=AbstractPlus

110. Merck & Co., Inc. Mevacor (lovastatin) tablets prescribing information. White House Station, NJ; 2005 Nov.

111. Bristol-Myers Squibb Company. Pravachol (pravastatin sodium) tablets prescribing information. Princeton, NJ; 2005 Aug.

112. Merck & Co., Inc. Zocor (simvastatin) tablets prescribing information. Whitehouse Station, NJ; 2008 Jun.

113. Herd JA, Ballantyne CM, Farmer JA et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997; 80:278-86. http://www.ncbi.nlm.nih.gov/pubmed/9264419?dopt=AbstractPlus

114. MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet. 1994; 344:633-8. http://www.ncbi.nlm.nih.gov/pubmed/7864934?dopt=AbstractPlus

115. Pitt B, Mancini GBJ, Ellis SG et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995; 26:1133-9. http://www.ncbi.nlm.nih.gov/pubmed/7594023?dopt=AbstractPlus

116. Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995; 75:455-9. http://www.ncbi.nlm.nih.gov/pubmed/7863988?dopt=AbstractPlus

117. Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995; 91:2528-40. http://www.ncbi.nlm.nih.gov/pubmed/7743614?dopt=AbstractPlus

118. Salonen R, Nyyssonen K, Porkkala-Sarataho E et al. The Kuopio Atherosclerosis Prevention Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 1995; 76:34-9C.

119. Blankenhorn DH, Azen SP, Kramsch DM et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 1993; 119:969-76.

120. Waters D, Higginson L, Gladstone P et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation. 1995; 92:2404-10.

121. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990; 323:1289-98. http://www.ncbi.nlm.nih.gov/pubmed/2215615?dopt=AbstractPlus

122. Furberg CD, Adams HP, Applegate WB et al for the Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994; 90:1679-87. http://www.ncbi.nlm.nih.gov/pubmed/7734010?dopt=AbstractPlus

123. DeGroot E, Jukema JW, Montauban AD et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998; 31:1561-7. http://www.ncbi.nlm.nih.gov/pubmed/9626835?dopt=AbstractPlus

124. Glorioso N, Troffa C, Filigheddu F et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999; 34:1281-6. http://www.ncbi.nlm.nih.gov/pubmed/10601131?dopt=AbstractPlus

125. Borghi C, Prandin MG, Costa FV et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000; 35:549-55. http://www.ncbi.nlm.nih.gov/pubmed/10774784?dopt=AbstractPlus

126. Ridker PM, Rifai N, Pfeffer MA et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999; 100:230-5. http://www.ncbi.nlm.nih.gov/pubmed/10411845?dopt=AbstractPlus

127. Kluft C, de Maat MPM, Leuven JAG et al. Statins and C-reactive protein. Lancet. 1999; 353:1274-5.

128. Novartis Pharmaceuticals Corporation. Lescol (fluvastatin sodium) capsules and Lescol XL (fluvastatin sodium) extended-release tablets prescribing information. East Hanover, NJ; 2006 Apr.

129. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol. 1994; 73:3-11D.

130. Desager JP, Horsmans. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 1996; 31:348-71. http://www.ncbi.nlm.nih.gov/pubmed/9118584?dopt=AbstractPlus

131. Corsini A, Besllosta S, Baetta R et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999; 84:413-28. http://www.ncbi.nlm.nih.gov/pubmed/10665838?dopt=AbstractPlus

132. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin Pharmacokinet. 1997; 32:403-25. http://www.ncbi.nlm.nih.gov/pubmed/9160173?dopt=AbstractPlus

133. Walker JF, Tobert JA. The clinical efficacy and safety of lovastatin and MK-733--an overview. Eur Heart J. 1987; 8(Suppl E):93-6.

134. Bayer, West Haven, CT: Personal communication.

135. Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs. 1998; 56(suppl 1): 15-23. http://www.ncbi.nlm.nih.gov/pubmed/9740537?dopt=AbstractPlus

136. Andrx Laboratories, Inc. Altocor (lovastatin) extended-release tablets prescribing information. Weston, FL; 2002 Jul.

137. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health-Syst Pharm. 1998; 55:2253-67. http://www.ncbi.nlm.nih.gov/pubmed/9825877?dopt=AbstractPlus

138. White CM. An evaluation of CYP3A4 drug interactions with HMG-CoA reductase inhibitors. Formulary. 2000; 34:343-52.

139. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999; 341:498-511. http://www.ncbi.nlm.nih.gov/pubmed/10441607?dopt=AbstractPlus

140. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther. 1998; 80:1-34.

200. Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. Rockville, MD; 2012 Feb 28. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm

201. Food and Drug Administration. FDA expands advice on statin risks. Rockville, MD; 2012 Feb 27. From FDA website. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm

202. McKenney JM, Davidson MH, Jacobson TA et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006; 97(suppl):89-94C.

309. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015; 372:2387-97. http://www.ncbi.nlm.nih.gov/pubmed/26039521?dopt=AbstractPlus

336. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380:581-90. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3437972&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/22607822?dopt=AbstractPlus

337. Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-78. http://www.ncbi.nlm.nih.gov/pubmed/16214597?dopt=AbstractPlus

338. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670-81. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2988224&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/21067804?dopt=AbstractPlus

339. Wiggins BS, Saseen JJ, Page RL et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016; 134:e468-e495.

350. Stone NJ, Robinson J, Lichtenstein AH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; :. http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a

351. Stone NJ, Robinson JG, Lichtenstein AH et al. Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Synopsis of the 2013 ACC/AHA Cholesterol Guideline. Ann Intern Med. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24474185?dopt=AbstractPlus

352. Eckel RH, Jakicic JM, Ard JD et al. 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:2960-84. http://www.ncbi.nlm.nih.gov/pubmed/24239922?dopt=AbstractPlus

353. ACCORD Study Group, Ginsberg HN, Elam MB et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1563-74. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2879499&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/20228404?dopt=AbstractPlus

354. AIM-HIGH Investigators, Boden WE, Probstfield JL et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011; 365:2255-67. http://www.ncbi.nlm.nih.gov/pubmed/22085343?dopt=AbstractPlus

356. Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123:2292-333. http://www.ncbi.nlm.nih.gov/pubmed/21502576?dopt=AbstractPlus

357. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011; 128 Suppl 5:S213-56. http://www.ncbi.nlm.nih.gov/pubmed/22084329?dopt=AbstractPlus

369. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014; 371:203-12. http://www.ncbi.nlm.nih.gov/pubmed/25014686?dopt=AbstractPlus

371. Anderson TJ, Boden WE, Desvigne-Nickens P et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014; 371:288-90. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4156937&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/25014706?dopt=AbstractPlus

373. GlaxoSmithKline. Lovaza (omega-3-acid ethyl esters) capsules prescribing information. Research Triangle Park, NC; 2014 May.

374. Aegerion Pharmaceuticals, Inc. Juxtapid (lomitapide mesylate) capsules prescribing information. Cambridge, MA; 2013 Apr.

387. Wanner C, Krane V, März W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238-48. http://www.ncbi.nlm.nih.gov/pubmed/16034009?dopt=AbstractPlus

400. Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139:e1082-e1143. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=PMC7403606&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/30586774?dopt=AbstractPlus

405. US Food and Drug Administration. FDA Drug Safety Communication: FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy; still advises most pregnant patients should stop taking statins. Silver Spring, MD; 2021 July 20. From FDA website. Accessed 2021 Sept 9. https://www.fda.gov/safety/medical-product-safety-information/statins-drug-safety-communication-fda-requests-removal-strongest-warning-against-using-cholesterol

Frequently asked questions

View more FAQ